Calcifediol treatment and COVID-19-related outcomes

Context: COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity. Objective: This work aims to elucidate the effect of 25(OH)D3 (calcifediol) treatment on COVID-19-related...

Descripción completa

Detalles Bibliográficos
Autores: Nogués Solán, Xavier, Ovejero Crespo, Diana, Pineda-Moncusí, Marta, Bouillon, Roger, Arenas, María Dolores (Arenas Jiménez), Pascual Santos, Julio, Ribes, Anna, Güerri Fernández, Roberto, Villar García, Judit, Rial, Abora, Gimenez-Argente, Carme, Cos, Maria Lourdes, Rodriguez-Morera, Jaime, Campodarve, Isabel, Quesada-Gómez, J.M., Garcia Giralt, Natàlia
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/52640
Acceso en línea:http://hdl.handle.net/10230/52640
http://dx.doi.org/10.1210/clinem/dgab405
Access Level:acceso abierto
Palabra clave:COVID-19
ICU admission
Calcifediol
Mortality
Vitamin D
id ES_c4a7494c1f2131cc81ae9dfd3d03574e
oai_identifier_str oai:recercat.cat:10230/52640
network_acronym_str ES
network_name_str España
repository_id_str
spelling Calcifediol treatment and COVID-19-related outcomesNogués Solán, XavierOvejero Crespo, DianaPineda-Moncusí, MartaBouillon, RogerArenas, María Dolores (Arenas Jiménez)Pascual Santos, JulioRibes, AnnaGüerri Fernández, RobertoVillar García, JuditRial, AboraGimenez-Argente, CarmeCos, Maria LourdesRodriguez-Morera, JaimeCampodarve, IsabelQuesada-Gómez, J.M.Garcia Giralt, NatàliaCOVID-19ICU admissionCalcifediolMortalityVitamin DContext: COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity. Objective: This work aims to elucidate the effect of 25(OH)D3 (calcifediol) treatment on COVID-19-related outcomes. Methods: This observational cohort study was conducted from March to May 2020, among patients admitted to COVID-19 wards of Hospital del Mar, Barcelona, Spain. A total of 930 patients with COVID-19 were included; 92 were excluded because of previous calcifediol intake. Of the remaining 838, a total of 447 received calcifediol (532 μg on day 1 plus 266 μg on days 3, 7, 15, and 30), whereas 391 were not treated at the time of hospital admission (intention-to-treat). Of the latter, 53 patients were treated later during ICU admission and were allocated in the treated group in a second analysis. In healthy individuals, calcifediol is about 3.2-fold more potent on a weight basis than cholecalciferol. Main outcome measures were ICU admission and mortality. Results: ICU assistance was required by 102 (12.2%) participants. Out of 447 patients treated with calcifediol at admission, 20 (4.5%) required the ICU, compared to 82 (21%) out of 391 nontreated (P < .001). Logistic regression of calcifediol treatment on ICU admission, adjusted by age, sex, linearized 25-hydroxyvitamin D levels at baseline, and comorbidities showed that treated patients had a reduced risk of requiring the ICU (odds ratio [OR] 0.13; 95% CI 0.07-0.23). Overall mortality was 10%. In the intention-to-treat analysis, 21 (4.7%) out of 447 patients treated with calcifediol at admission died compared to 62 patients (15.9%) out of 391 nontreated (P = .001). Adjusted results showed a reduced mortality risk with an OR of 0.21 (95% CI, 0.10-0.43). In the second analysis, the obtained OR was 0.52 (95% CI, 0.27-0.99). Conclusion: In patients hospitalized with COVID-19, calcifediol treatment significantly reduced ICU admission and mortality.Oxford University Press20222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/52640http://dx.doi.org/10.1210/clinem/dgab405reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésJ Clin Endocrinol Metab. 2021 Sep 27;106(10):e4017-e4027© Oxford University Press. This is a pre-copyedited, author-produced version of an article accepted for publication in The Journal of clinical endocrinology and metabolism following peer review. The version of record Nogues X, Ovejero D, Pineda-Moncusí M, Bouillon R, Arenas D, Pascual J, Ribes A, Guerri-Fernandez R, Villar-Garcia J, Rial A, Gimenez-Argente C, Cos ML, Rodriguez-Morera J, Campodarve I, Quesada-Gomez JM, Garcia-Giralt N. Calcifediol treatment and COVID-19-related outcomes. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4017-e4027. DOI: 10.1210/clinem/dgab405 is available online at: https://academic.oup.com/jcem/article/106/10/e4017/6294179.info:eu-repo/semantics/openAccessoai:recercat.cat:10230/526402026-05-29T05:05:01Z
dc.title.none.fl_str_mv Calcifediol treatment and COVID-19-related outcomes
title Calcifediol treatment and COVID-19-related outcomes
spellingShingle Calcifediol treatment and COVID-19-related outcomes
Nogués Solán, Xavier
COVID-19
ICU admission
Calcifediol
Mortality
Vitamin D
title_short Calcifediol treatment and COVID-19-related outcomes
title_full Calcifediol treatment and COVID-19-related outcomes
title_fullStr Calcifediol treatment and COVID-19-related outcomes
title_full_unstemmed Calcifediol treatment and COVID-19-related outcomes
title_sort Calcifediol treatment and COVID-19-related outcomes
dc.creator.none.fl_str_mv Nogués Solán, Xavier
Ovejero Crespo, Diana
Pineda-Moncusí, Marta
Bouillon, Roger
Arenas, María Dolores (Arenas Jiménez)
Pascual Santos, Julio
Ribes, Anna
Güerri Fernández, Roberto
Villar García, Judit
Rial, Abora
Gimenez-Argente, Carme
Cos, Maria Lourdes
Rodriguez-Morera, Jaime
Campodarve, Isabel
Quesada-Gómez, J.M.
Garcia Giralt, Natàlia
author Nogués Solán, Xavier
author_facet Nogués Solán, Xavier
Ovejero Crespo, Diana
Pineda-Moncusí, Marta
Bouillon, Roger
Arenas, María Dolores (Arenas Jiménez)
Pascual Santos, Julio
Ribes, Anna
Güerri Fernández, Roberto
Villar García, Judit
Rial, Abora
Gimenez-Argente, Carme
Cos, Maria Lourdes
Rodriguez-Morera, Jaime
Campodarve, Isabel
Quesada-Gómez, J.M.
Garcia Giralt, Natàlia
author_role author
author2 Ovejero Crespo, Diana
Pineda-Moncusí, Marta
Bouillon, Roger
Arenas, María Dolores (Arenas Jiménez)
Pascual Santos, Julio
Ribes, Anna
Güerri Fernández, Roberto
Villar García, Judit
Rial, Abora
Gimenez-Argente, Carme
Cos, Maria Lourdes
Rodriguez-Morera, Jaime
Campodarve, Isabel
Quesada-Gómez, J.M.
Garcia Giralt, Natàlia
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
ICU admission
Calcifediol
Mortality
Vitamin D
topic COVID-19
ICU admission
Calcifediol
Mortality
Vitamin D
description Context: COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity. Objective: This work aims to elucidate the effect of 25(OH)D3 (calcifediol) treatment on COVID-19-related outcomes. Methods: This observational cohort study was conducted from March to May 2020, among patients admitted to COVID-19 wards of Hospital del Mar, Barcelona, Spain. A total of 930 patients with COVID-19 were included; 92 were excluded because of previous calcifediol intake. Of the remaining 838, a total of 447 received calcifediol (532 μg on day 1 plus 266 μg on days 3, 7, 15, and 30), whereas 391 were not treated at the time of hospital admission (intention-to-treat). Of the latter, 53 patients were treated later during ICU admission and were allocated in the treated group in a second analysis. In healthy individuals, calcifediol is about 3.2-fold more potent on a weight basis than cholecalciferol. Main outcome measures were ICU admission and mortality. Results: ICU assistance was required by 102 (12.2%) participants. Out of 447 patients treated with calcifediol at admission, 20 (4.5%) required the ICU, compared to 82 (21%) out of 391 nontreated (P < .001). Logistic regression of calcifediol treatment on ICU admission, adjusted by age, sex, linearized 25-hydroxyvitamin D levels at baseline, and comorbidities showed that treated patients had a reduced risk of requiring the ICU (odds ratio [OR] 0.13; 95% CI 0.07-0.23). Overall mortality was 10%. In the intention-to-treat analysis, 21 (4.7%) out of 447 patients treated with calcifediol at admission died compared to 62 patients (15.9%) out of 391 nontreated (P = .001). Adjusted results showed a reduced mortality risk with an OR of 0.21 (95% CI, 0.10-0.43). In the second analysis, the obtained OR was 0.52 (95% CI, 0.27-0.99). Conclusion: In patients hospitalized with COVID-19, calcifediol treatment significantly reduced ICU admission and mortality.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/52640
http://dx.doi.org/10.1210/clinem/dgab405
url http://hdl.handle.net/10230/52640
http://dx.doi.org/10.1210/clinem/dgab405
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4017-e4027
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418899506724864
score 15,812429

Similares en LA Referencia